Rep. April McClain Delaney Purchases Shares of Labcorp Holdings Inc. (NYSE:LH)

Representative April McClain Delaney (Democratic-Maryland) recently bought shares of Labcorp Holdings Inc. (NYSE:LH). In a filing disclosed on March 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Labcorp stock on February 4th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of EMCOR Group (NYSE:EME) on 2/27/2026.
• Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/27/2026.
• Purchased $1,001 – $15,000 in shares of Nasdaq (NASDAQ:NDAQ) on 2/27/2026.
• Sold $1,001 – $15,000 in shares of Morningstar (NASDAQ:MORN) on 2/25/2026.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of CDW (NASDAQ:CDW) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/23/2026.

Labcorp Price Performance

Shares of NYSE:LH opened at $270.59 on Wednesday. The firm has a market capitalization of $22.30 billion, a PE ratio of 25.87, a PEG ratio of 1.82 and a beta of 1.01. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72. The business’s 50 day moving average is $273.07 and its 200-day moving average is $269.74.

Labcorp (NYSE:LH) last issued its earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping the consensus estimate of $3.95 by $0.12. The firm had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.Labcorp’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the business earned $3.45 earnings per share. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Sell-side analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Friday, February 27th were given a $0.72 dividend. The ex-dividend date was Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is currently 27.53%.

Hedge Funds Weigh In On Labcorp

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LH. Caldwell Trust Co bought a new position in shares of Labcorp in the second quarter valued at approximately $25,000. JPL Wealth Management LLC bought a new stake in Labcorp during the 3rd quarter worth approximately $28,000. Financial Gravity Companies Inc. bought a new stake in Labcorp during the 2nd quarter worth approximately $26,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp during the 4th quarter valued at $26,000. Finally, Hilton Head Capital Partners LLC bought a new position in Labcorp in the 4th quarter valued at $27,000. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a research report on Tuesday, February 17th. JPMorgan Chase & Co. lifted their price objective on Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Weiss Ratings raised Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Robert W. Baird raised their target price on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Finally, Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Labcorp currently has an average rating of “Moderate Buy” and a consensus price target of $304.82.

Insiders Place Their Bets

In other news, EVP Brian J. Caveney sold 1,500 shares of the stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total transaction of $429,465.00. Following the sale, the executive vice president owned 30,107 shares in the company, valued at approximately $8,619,935.17. This represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the completion of the sale, the executive vice president owned 2,579 shares of the company’s stock, valued at approximately $734,782.89. This trade represents a 17.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 16,113 shares of company stock worth $4,547,450 in the last three months. Company insiders own 0.84% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.